All In Biotech

Drug Trial Radar · NCT04067336

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Last checked: Nov 21, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 263 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

263

Planned (sponsor's estimate)

Start

Sep 12, 2019

Primary completion

Oct 16, 2028

Study completion Oct 16, 2028

Sponsor

Lead sponsor
Kura Oncology, Inc.Industry
Sponsor type
Industry
First posted
Aug 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies. In the Main Study (including Phase 1a, Phase 1b, and Phase 2 portions), ziftomenib will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment. In Sub-studies 1 and 2, the effects of taking ziftomenib and other common drugs at the same time will be investigated in AML patients. In Sub-study 3, ziftomenib will be evaluated in patients with R/R acute lymphoblastic leukemia (ALL). In Sub-study 4, ziftomenib will be evaluated in patients with R/R AML with certain genetic mutations.

Conditions

  • Advanced Malignant Neoplasm
  • Acute Myeloid Leukemia
  • Mixed Lineage Leukemia
  • Mixed Lineage Acute Leukemia
  • Acute Leukemia of Ambiguous Lineage
  • Mixed Phenotype Acute Leukemia
  • Acute Lymphoblastic Leukemia

Interventions

  • ZiftomenibDrug

    Oral administration

  • MidazolamDrug

    Oral administration

  • ItraconazoleDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: Maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D)Time frame: Dose Limiting Toxicities (DLTs) will be evaluated during the first 28 days (1 cycle)
  2. Phase 1b: Number of patients who experience Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first.
  3. Phase 1b: Minimum biologically effective doseTime frame: For at least 12 months following end of treatment
  4. Phase 1a, 1b, and 2: Evidence of anti-leukemia activityTime frame: For at least 12 months following end of treatment
  5. Sub-study 1: Time to observed maximum plasma concentration (Tmax) of ziftomenib and midazolamTime frame: Cycle 1 on Days 1 and 15 at predose and postdose
  6. Sub-study 1: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib and midazolamTime frame: Cycle 1 on Days 1 and 15 at predose and postdose
  7. Sub-study 1: Maximum observed plasma concentration (Cmax) of ziftomenib and midazolamTime frame: Cycle 1 on Days 1 and 15 at predose and postdose
  8. Sub-study 2: Time to observed maximum plasma concentration (Tmax) of ziftomenib and itraconazoleTime frame: Cycle 1 on Days 1, 15, and 22 at predose and postdose
  9. Sub-study 2: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib and itraconazoleTime frame: Cycle 1 on Days 1, 15, and 22 at predose and postdose
  10. Sub-study 2: Maximum observed plasma concentration (Cmax) of ziftomenib and itraconazoleTime frame: Cycle 1 on Days 1, 15, and 22 at predose and postdose
  11. Sub-study 3: Minimum biologically effective dose (MBED) and/or the recommended Phase 2 dose (RP2D)Time frame: During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first
  12. Sub-study 3: Minimum biologically effective dose (MBED) and/or the recommended Phase 2 dose (RP2D)Time frame: For at least 12 months following end of treatment
  13. Sub-study 3: Change in Eastern Cooperative Oncology Group (ECOG) statusTime frame: Timeframe: from Baseline to End of Treatment
  14. Sub-study 3: Time to observed maximum plasma concentration (Tmax) of ziftomenibTime frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards
  15. Sub-study 3: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenibTime frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards
  16. Sub-study 3: Maximum observed plasma concentration (Cmax) of ziftomenibTime frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards.
  17. Sub-study 4: Complete remission (CR) and complete remission with partial hematologic recovery (CRh)Time frame: For at least 12 months following end of treatment

Locations

43 sites in 7 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • UCLA Ronald Reagan Medical Center

    Los Angeles, California

  • Mayo Clinic

    Jacksonville, Florida

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    Chicago, Illinois

  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan Hospitals

    Ann Arbor, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Hackensack University Medical Center - John Theurer Cancer Center

    Hackensack, New Jersey

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Weill Cornell Medical College - NY Presbyterian Hospital

    New York, New York

  • The Mount Sinai Hospital

    New York, New York

  • Duke Cancer Institute

    Durham, North Carolina

  • Oklahoma University Health - Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • Harold C. Simmons Comprehensive Cancer Center - UT Southwestern Medical Center

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • AZ Delta - Campus Rumbeke

    Roeselare, Belgium

  • Queen Elizabeth II Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • Hopital Maisonneuve-Rosemont

    Montreal, Quebec, Canada

  • Hopital de l'Enfant-Jesus - Centre Integre en Cancerologie du CHU de Quebec - Universite Laval

    Québec, Quebec, Canada

  • Centre Hospitalier Universitaire de Lille

    Lille, France

  • Centre Hospitalier Universitaire de Nantes

    Nantes, France

  • Hopital Saint Louis

    Paris, France

  • Magendie Hopital Haut-Leveque

    Pessac, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • Institut Gustave Roussy

    Villejuif, France

  • University Medicine Greifswald

    Greifswald, Germany

  • Medizinische Hochsschule Hannover

    Hanover, Germany

  • Institute of Hematology and Medical Oncology "L. and A. Seragnoli"

    Bologna, Italy

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"

    Meldola, Italy

  • UO Ematologia Ospedale di Ravenna

    Ravenna, Italy

  • Institution Fondazione Policlinico Tor Vergata

    Roma, Italy

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Universitat de Barcelona

    Barcelona, Spain

  • MD Anderson Cancer Center

    Madrid, Spain

  • Hospital Universitario HM Sanchinarro

    Madrid, Spain

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.